NCT02608970View on ClinicalTrials.gov

Safety and Tolerability Study of BMS-986177 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

July 23, 2017

Study Completion Date

July 23, 2017

Conditions
Thrombosis
Interventions
DRUG

BMS-986177

OTHER

Placebo

Trial Locations (1)

2060

SGS Belgium NV, Antwerp

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT02608970 - Safety and Tolerability Study of BMS-986177 in Healthy Subjects | Biotech Hunter | Biotech Hunter